Our Background



                                                                                                                                                                Isolation of human gut bacteria with specific properties                                                                   (i.e. immune stimulatory and specific binding properties)


Isolation of strains expressing specific carbohydrate antigens

In vitro and In vivo evaluation of probiotic properties

Safety assessment including toxicological studies


Risk assessment and risk group downgrading of bacteria species, e.g. Bacteroides xylanisolvens


Obtaining Novel Food Status (EU) and GRAS Status (US) for a new Microorganism (DSM  23964) 

Running probiotic specific Human Clinical Studies


Development of production processes from the lab to industrial scale